AU2001235761A1 - Diagnosis of breast cancer using bcmp-11 as marker - Google Patents

Diagnosis of breast cancer using bcmp-11 as marker

Info

Publication number
AU2001235761A1
AU2001235761A1 AU2001235761A AU3576101A AU2001235761A1 AU 2001235761 A1 AU2001235761 A1 AU 2001235761A1 AU 2001235761 A AU2001235761 A AU 2001235761A AU 3576101 A AU3576101 A AU 3576101A AU 2001235761 A1 AU2001235761 A1 AU 2001235761A1
Authority
AU
Australia
Prior art keywords
bcmp
breast cancer
diagnosis
marker
immunospecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235761A
Inventor
Robert Simon Boyd
Alasdair Craig Stamps
Jonathan Alexander Terrett
Kerry Louise Tyson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2001235761A1 publication Critical patent/AU2001235761A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention provides the use of a protein found in breast cancer cell membranes, known as BCMP 11, in the diagnosis, screening, treatment and prophylaxis of breast cancer or prostate cancer, as well as compositions comprising BCMP 11, including vaccines and antibodies that are immunospecific for BCMP 11.
AU2001235761A 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-11 as marker Abandoned AU2001235761A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0004576.5A GB0004576D0 (en) 2000-02-25 2000-02-25 Proteins
GB0004576 2000-02-25
PCT/GB2001/000730 WO2001063289A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-11 as marker

Publications (1)

Publication Number Publication Date
AU2001235761A1 true AU2001235761A1 (en) 2001-09-03

Family

ID=9886470

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001233917A Abandoned AU2001233917A1 (en) 2000-02-25 2001-02-21 Bcmp-7 as marker for diagnosis of breast cancer
AU2001235761A Abandoned AU2001235761A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-11 as marker
AU2001233912A Abandoned AU2001233912A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-81 as marker

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001233917A Abandoned AU2001233917A1 (en) 2000-02-25 2001-02-21 Bcmp-7 as marker for diagnosis of breast cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001233912A Abandoned AU2001233912A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-81 as marker

Country Status (8)

Country Link
US (2) US20020111303A1 (en)
EP (2) EP1259814B1 (en)
AT (1) ATE306668T1 (en)
AU (3) AU2001233917A1 (en)
DE (1) DE60113968T2 (en)
ES (1) ES2249410T3 (en)
GB (1) GB0004576D0 (en)
WO (3) WO2001063289A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US7608696B2 (en) * 2001-10-26 2009-10-27 Dana-Farber Cancer Institute, Inc. IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
US20080081037A1 (en) * 2002-12-23 2008-04-03 Johannes Grosse Methods and Agents for Diagnosis and Prevention, Amelioration or Treatment of Goblet Cell-Related Disorders
KR20060013425A (en) 2003-05-29 2006-02-09 밀레니엄 파머슈티컬스 인코퍼레이티드 Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20050277167A1 (en) * 2004-03-11 2005-12-15 Bachinger Hans P Prolyl 3-hydroxylases
GB0616929D0 (en) * 2006-08-26 2006-10-04 Univ Liverpool Antibodies, assays and hybridomas
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3588043T2 (en) * 1984-01-06 1996-03-21 Univ California CYTOKERATIN TUMOR MARKER AND TEST TO DETECT IT.
EP0929575A4 (en) * 1996-08-23 2004-09-08 Human Genome Sciences Inc Novel human growth factors
AU9283198A (en) * 1997-10-08 1999-04-27 Protegene Inc. Human proteins having transmembrane domains and cdnas encoding these prot eins
DE19817557A1 (en) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences from ovarian tumor tissue
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU2495200A (en) * 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of tumor
EP1159619A2 (en) * 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Methods of diagnosing and treating breast cancer

Also Published As

Publication number Publication date
GB0004576D0 (en) 2000-04-19
ATE306668T1 (en) 2005-10-15
AU2001233917A1 (en) 2001-09-03
AU2001233912A1 (en) 2001-09-03
EP1259814B1 (en) 2005-10-12
ES2249410T3 (en) 2006-04-01
DE60113968D1 (en) 2006-02-23
US20020111303A1 (en) 2002-08-15
DE60113968T2 (en) 2006-06-22
EP1257827A1 (en) 2002-11-20
EP1259814A1 (en) 2002-11-27
WO2001063288A1 (en) 2001-08-30
WO2001063290A1 (en) 2001-08-30
US20030017456A1 (en) 2003-01-23
WO2001063289A1 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
YU9404A (en) Peptide-based multimeric targeted contrast agents
YU37304A (en) Specific binding agents of human angiopoietin-2
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
HK1040983A1 (en) Quinones for treatment of diseases.
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
YU68602A (en) Monoclonal antibodies to the human ldl receptor, their production and use
MXPA02011563A (en) Compositions and methods for the therapy and diagnosis of breast cancer.
TR200200278T2 (en) Calcilitic compositions
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
ATE298244T1 (en) MONOCLONAL ANTIBODIES WITH SELECTIVE BINDING TO VGF AND USE FOR THE TREATMENT OF VGF DISEASES
AU2001280443A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
WO2002102849A3 (en) Bcmp-101, a cancer associated protein
TW200635952A (en) Specific binding agents of human angiopoietin-2
ATE366937T1 (en) CANCER-ASSOCIATED PROTEIN